Clinical Trials Logo

Clinical Trial Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05813925
Study type Interventional
Source Novo Nordisk A/S
Contact Novo Nordisk
Phone (+1) 866-867-7178
Email clinicaltrials@novonordisk.com
Status Recruiting
Phase Phase 3
Start date April 3, 2023
Completion date March 17, 2025

See also
  Status Clinical Trial Phase
Completed NCT03629301 - Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults N/A
Completed NCT05607680 - A Study of IBI362 in Participants With Obesity or Overweight Phase 3
Completed NCT05153590 - A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
Recruiting NCT05996848 - A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight Phase 3